文章摘要
北京65例新型冠状病毒肺炎患者临床特征分析
Analysis on clinical characteristics of 65 COVID-19 patients in Beijing
  
DOI:10.3969/j.issn.1007-8134.2020.03.003
中文关键词: 新型冠状病毒  新型冠状病毒肺炎  临床特征  北京
英文关键词: SARS-CoV-2  COVID-19  clinical characteristic  Beijing
基金项目:国家自然科学基金创新群体项目(81721002);国家重点研发计划(2020YFC0841900)
作者单位
曹文静 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
王嗣予 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
杨 涛 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
范 兴 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
张 超 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
施 明 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
孟繁平 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
徐 哲 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
宋锦文 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
王福生 国家感染病临床医学研究中心 中国人民解放军总医院第五医学中心感染性疾病诊疗与研究中心 
摘要点击次数: 1335
全文下载次数: 718
中文摘要:
      目的 分析新型冠状病毒肺炎(COVID-19)确诊病例的流行病学、临床症状及实验室检查指标,为全面总结COVID-19的临床特征与正确评价患者预后提供依据。方法 采用回顾性研究方法,以2020年1月20日—2月29日期间本中心收治的65例COVID-19患者为研究对象,根据临床症状将患者分为轻型组(18例),普通型组(31例)和重/危重型组(16例)3组,对所有患者流行病学、临床症状及实验室检查指标进行分析。结果 65例COVID-19患者中男37例(57%),女28例(43%);年龄3~85岁,平均(46.63±18.63)岁。从出现症状到入院平均时长为(7.00±5.02)d,住院时间为(17.07±10.51)d。3组间及两两分组之间年龄比较差异均具有统计学意义(P均<0.05),即年龄越大的患者病情越重。相较于轻型组和普通型组患者,重/危重型组患者合并有更多的基础疾病。COVID-19患者临床症状以发热(75%)、咳嗽(57%)、肌痛或乏力(43%)为主,其余症状还包括咳痰,头痛,胸闷、气短及腹泻等。24例(37%)有武汉暴露史,19例(29%)有家族聚集性接触史。实验室检查结果显示:3组患者WBC和淋巴细胞绝对计数降低;D-二聚体,CRP,IL-6及ESR水平升高。在重/危重型组患者中,8例(50%)出现淋巴细胞绝对计数下降,9例(9/14,64%)出现D-二聚体水平升高。此外,重/危重型组患者中,CRP、IL-6、降钙素原和ESR水平都显著升高。COVID-19患者住院时间与淋巴细胞绝对计数呈负相关。结论 COVID-19患者的临床特点复杂,一般以发热、咳嗽、肌痛或乏力为主要症状。与轻型组和普通型组患者相比,重/危重型组患者淋巴细胞绝对计数减少和炎症相关的指标上升更显著,免疫平衡失调,可能影响患者的疾病进展、恢复和预后。
英文摘要:
      Objective To analyze the epidemiology, clinical characteristics and laboratory testing parameters of novel coronavirus 2019 (COVID-19) patients, and provide evidence for comprehensive summary of clinical characteristics of COVID-19 and proper evaluation of patient’s prognosis. Methods From January 20th to February 29th, 2020, a total of 65 patients with COVID-19 admitted to our center were included in this retrospective study. The included patients were divided into 3 groups according to their clinical symptoms: mild group (n=18), common group (n=31) and severe/critical group (n=16). The epidemiology, clinical symptoms and laboratory testing parameters of all patients were analyzed. Results Among 65 COVID-19 patients, there were 37 men (57%) and 28 women (43%). Their age ranged 3-85 years, with a mean of (46.63±18.63) years. The average duration of symptoms before admission was (7.00±5.02) days and the length of hospital stay was (17.07±10.51) days. There were statistical differences in age among 3 groups and between every 2 groups (P<0.05). That is the older the patients were, the more severe the disease was. Severe/critical ill patients had more comorbidities of underlying diseases than mild and common patients. The clinical symptoms of COVID-19 patients were mainly fever (75%), cough (57%), myalgia or fatigue (43%). Other symptoms included expectoration, headache, fatigue, myalgia, shortness of breath, diarrhea, etc. Among them, 24 (37%) patients had a history of Wuhan exposure and 19 (29%) patients had a familial cluster of infection. Laboratory testing results showed that absolute count of white blood cells and lymphocytes was decreased in all 3 groups of COVID-19 patients; the levels of D-dimer, CRP, IL-6, and ESR were increased. Among the severe/critical ill patients, 8 (50%) cases had a decrease in absolute number of lymphocytes, and 9 (9/14, 64%) cases had an increased level of D-dimer. In addition, CRP, IL-6, procalcitonin and ESR were significantly increased in severe/critical ill patients. The length of hospital stay was negatively correlated with the absolute number of lymphocytes in COVID-19 patients. Conclusions The clinical characteristics of COVID-19 are complicated and the main symptoms include fever, cough, myalgia or fatigue. Compared with mild and common patients, severe/critical ill patients exhibit significant lymphopenia and increased levels of inflammation-related indices. The dysregulation of the immune system may affect the progression, recovery and outcome of COVID-19 patients.
HTML   查看全文   下载PDF阅读器
关闭